Javascript must be enabled for the correct page display
Skip to Content
navigation opener
Publications

BPI Benchmark Report: The Future of Bioprocessing

August 2026

Sponsored by Bora Biologics
Explore emerging trends and strategic shifts shaping biopharma — and why commercialization readiness, regulatory confidence, and manufacturing continuity now matter earlier than ever.

Why This Report Matters
The biologics landscape is shifting. Sponsors are facing tighter timelines, more investor scrutiny, higher regulatory expectations, and greater pressure to scale without disruption.

This report highlights the trends shaping bioprocessing today — and includes Bora Biologics’ perspective on how CDMO partnerships are evolving to support commercial readiness from the earliest stages of development.

Bora Biologics’ Perspective
Designed for Commercialization. From Day One.

At Bora Biologics, we believe execution is the new differentiator in commercial biologics. Our integrated platform connects early-stage development in Taiwan with U.S.-based GMP manufacturing in San Diego and Rockville to support programs from first-in-human through commercial supply.

  • Integrated early development through commercial manufacturing
  • Bi-coastal U.S. FDA-registered biologics platform
  • Inspection-proven operations supporting global markets

Featured in the Report

Designed for Commercialization from Day 1: Execution in the New Differentiator in Commercial Biologics

Bora Biologics is Redefining CDMO Partnership in a Maturing Biotech Landscape

Download Full Report at BPI Website

Want to discuss your commercialization strategy?
Schedule a meeting with us to discuss tech transfer, GMP manufacturing, PPQ readiness, and long-term supply planning.

Filter

Bora Biologics

the logical choice

Join the ranks of biopharma pioneers who trust us.
Explore how we minimize risks and accelerate your success.

Partner with us

Client-Centric

100% commitment to supporting your success

We have been the client, bringing multiple biologics from IND to BLA. Your needs and goals are at the forefront of our approach. By involving you in every step of the process, we ensure transparency and alignment, reducing the likelihood of misunderstandings and ensuring the outcome meets your expectations.

Experience

15+ years developing & manufacturing biologics

We have honed our ability to navigate complexities. Our track record from concept to commercialization means we can apply best practices and lessons learned, ensuring smoother project execution.

Expertise

Over 200 seasoned scientists & regulatory professionals

Our team exudes deep knowledge and specialized skills. This expertise allows us to foresee potential challenges and implement proactive solutions, reducing the likelihood of setbacks.

Commercial-Ready

2 US FDA registered GMP manufacturing facilities

We focus on delivering solutions that are ready for market. With clinical to commercial scale facilities consistently meeting compliance standards, we ensure your project is primed for success, minimizing the risk of costly revisions or delays.

Allied

access to global CDMO resources

Our partnership with Bora Pharmaceuticals provides additional resources and insights. This network enables us to leverage shared knowledge and expertise, further mitigating risks and accelerating the overall success of your project.